Radosa Julia Caroline, Radosa Marc Philipp, Schweitzer Pascal Albert, Juhasz-Boess Ingolf, Rimbach Stefan, Solomayer Erich-Franz
Department of Gynecology and Obstetrics, Saarland University Hospital, Kirrbergerstraße 100, 66421, Homburg, Germany.
Department of Gynecology, Agaplesion Diakonie Hospital Kassel, Herkulesstraße 34, 34119, Kassel, Germany.
Arch Gynecol Obstet. 2018 May;297(5):1255-1264. doi: 10.1007/s00404-018-4709-5. Epub 2018 Mar 8.
The purpose of this survey was to assess the opinions of members of the German Society of Gynecologic Endoscopy (AGE) regarding the laparoscopic treatment of ovarian malignancies and current practice at their institutions.
Between February and October 2015, the AGE sent an anonymous online survey via mail to its members. The questionnaire solicited participants' opinions about the laparoscopic treatment of ovarian cancers according to T stage and borderline tumors, and information about current practice at their institutions. Participants were also asked their opinions on currently available data on this issue.
Of 228 AGE members who completed the survey, 132 (58%) were fellows or attending physicians and 156 (68%) worked at university hospitals or tertiary referral centers. Most [212 (93%)] respondents stated that < 10% of all ovarian cancer cases were currently treated laparoscopically at their institutions. Most participants indicated that T1 (a, b, c) tumors [145 (64%)] and ovarian borderline tumors [206 (90%)], but not T2 [48 (21%)] or T3/4 [9 (4%) ovarian tumors] should or could be treated laparoscopically. One hundred seventy-two (75%) participants considered currently available data on this topic to be insufficient and 152 (66%) stated that they would take part in a clinical trial assessing a laparoscopic approach to T1/2 ovarian cancer.
According to this survey, to the opinion of the majority of AGE members, laparoscopy might be a considerable option for the treatment of early ovarian malignancies and borderline tumors and should be evaluated further in future studies.
本次调查旨在评估德国妇科内镜学会（AGE）成员对卵巢恶性肿瘤腹腔镜治疗及其所在机构当前实践的看法。
2015年2月至10月期间，AGE通过邮件向其成员发送了一份匿名在线调查问卷。该问卷征求了参与者对根据T分期的卵巢癌腹腔镜治疗和交界性肿瘤的意见，以及有关其所在机构当前实践的信息。参与者还被问及他们对该问题当前可用数据的看法。
在完成调查的228名AGE成员中，132名（58%）是研究员或主治医师，156名（68%）在大学医院或三级转诊中心工作。大多数[212名（93%）]受访者表示，目前其所在机构所有卵巢癌病例中<10%采用腹腔镜治疗。大多数参与者指出，T1（a、b、c）期肿瘤[145名（64%）]和卵巢交界性肿瘤[206名（90%）]，但T2期[48名（21%）]或T3/4期[9名（4%）卵巢肿瘤]不应或不能采用腹腔镜治疗。172名（75%）参与者认为该主题的当前可用数据不足，152名（66%）表示他们将参加一项评估T1/2期卵巢癌腹腔镜治疗方法的临床试验。
根据本次调查，大多数AGE成员认为，腹腔镜检查可能是早期卵巢恶性肿瘤和交界性肿瘤治疗的一个重要选择，应在未来研究中进一步评估。
